Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial

L. Rob, D. Cibula, P. Knapp, P. Mallmann, J. Klat, L. Minar, P. Bartos, J. Chovanec, P. Valha, M. Pluta, Z. Novotny, J. Spacek, B. Melichar, D. Kieszko, J. Fucikova, T. Hrnciarova, RP. Korolkiewicz, M. Hraska, J. Bartunkova, R. Spisek

. 2022 ; 10 (1) : . [pub] -

Jazyk angličtina Země Velká Británie

Typ dokumentu klinické zkoušky, fáze II, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22011514

BACKGROUND: Most patients with epithelial ovarian cancer (EOC) relapse despite primary debulking surgery and chemotherapy (CT). Autologous dendritic cell immunotherapy (DCVAC) can present tumor antigens to elicit a durable immune response. We hypothesized that adding parallel or sequential DCVAC to CT stimulates antitumor immunity and improves clinical outcomes in patients with EOC. Based on the interim results of sequential DCVAC/OvCa administration and to accommodate the increased interest in maintenance treatment in EOC, the trial was amended by adding Part 2. METHODS: Patients with International Federation of Gynecology and Obstetrics stage III EOC (serous, endometrioid, or mucinous), who underwent cytoreductive surgery up to 3 weeks prior to randomization and were scheduled for first-line platinum-based CT were eligible. Patients, stratified by tumor residuum (0 or <1 cm), were randomized (1:1:1) to DCVAC/OvCa parallel to CT (Group A), DCVAC/OvCa sequential to CT (Group B), or CT alone (Group C) in Part 1, and to Groups B and C in Part 2. Autologous dendritic cells for DCVAC were differentiated from patients' CD14+ monocytes, pulsed with two allogenic OvCa cell lines (SK-OV-3, OV-90), and matured in the presence of polyinosinic:polycytidylic acid. We report the safety outcomes (safety analysis set, Parts 1 and 2 combined) along with the primary (progression-free survival (PFS)) and secondary (overall survival (OS)) efficacy endpoints. Efficacy endpoints were assessed in the modified intention-to-treat (mITT) analysis set in Part 1. RESULTS: Between November 2013 and March 2016, 99 patients were randomized. The mITT (Part 1) comprised 31, 29, and 30 patients in Groups A, B, and C, respectively. Baseline characteristics and DCVAC/OvCa exposure were comparable across the treatment arms. DCVAC/OvCa showed a good safety profile with treatment-emergent adverse events related to DCVAC/OvCa in 2 of 34 patients (5.9%) in Group A and 2 of 53 patients (3.8%) in Group B. Median PFS was 20.3, not reached, and 21.4 months in Groups A, B, and C, respectively. The HR (95% CI) for Group A versus Group C was 0.98 (0.48 to 2.00; p=0.9483) and the HR for Group B versus Group C was 0.39 (0.16 to 0.96; p=0.0336). This was accompanied by a non-significant trend of improved OS in Groups A and B. Median OS was not reached in any group after a median follow-up of 66 months (34% of events). CONCLUSIONS: DCVAC/OvCa and leukapheresis was not associated with significant safety concerns in this trial. DCVAC/OvCa sequential to CT was associated with a statistically significant improvement in PFS in patients undergoing first-line treatment of EOC. TRIAL REGISTRATION NUMBER: NCT02107937, EudraCT2010-021462-30.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011514
003      
CZ-PrNML
005      
20220506131510.0
007      
ta
008      
220425s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/jitc-2021-003190 $2 doi
035    __
$a (PubMed)34992091
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Rob, Lukas $u Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic
245    10
$a Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial / $c L. Rob, D. Cibula, P. Knapp, P. Mallmann, J. Klat, L. Minar, P. Bartos, J. Chovanec, P. Valha, M. Pluta, Z. Novotny, J. Spacek, B. Melichar, D. Kieszko, J. Fucikova, T. Hrnciarova, RP. Korolkiewicz, M. Hraska, J. Bartunkova, R. Spisek
520    9_
$a BACKGROUND: Most patients with epithelial ovarian cancer (EOC) relapse despite primary debulking surgery and chemotherapy (CT). Autologous dendritic cell immunotherapy (DCVAC) can present tumor antigens to elicit a durable immune response. We hypothesized that adding parallel or sequential DCVAC to CT stimulates antitumor immunity and improves clinical outcomes in patients with EOC. Base $a BACKGROUND Most patients with epithelial ovarian cancer EOC relapse despite primary debulking surgery and chemotherapy CT Autologous dendritic cell immunotherapy DCVAC can present tumor antigens to elicit a durable immune response We hypothesized that adding parallel or sequential DCVAC to CT stimulates antitumor immunity and improves clinical outcomes in patients with EOC Based on the i $a BACKGROUND: Most patients with epithelial ovarian cancer (EOC) relapse despite primary debulking surgery and chemotherapy (CT). Autologous dendritic cell immunotherapy (DCVAC) can present tumor antigens to elicit a durable immune response. We hypothesized that adding parallel or sequential DCVAC to CT stimulates antitumor immunity and improves clinical outcomes in patients with EOC. Based on the interim results of sequential DCVAC/OvCa administration and to accommodate the increased interest in maintenance treatment in EOC, the trial was amended by adding Part 2. METHODS: Patients with International Federation of Gynecology and Obstetrics stage III EOC (serous, endometrioid, or mucinous), who underwent cytoreductive surgery up to 3 weeks prior to randomization and were scheduled for first-line platinum-based CT were eligible. Patients, stratified by tumor residuum (0 or <1 cm), were randomized (1:1:1) to DCVAC/OvCa parallel to CT (Group A), DCVAC/OvCa sequential to CT (Group B), or CT alone (Group C) in Part 1, and to Groups B and C in Part 2. Autologous dendritic cells for DCVAC were differentiated from patients' CD14+ monocytes, pulsed with two allogenic OvCa cell lines (SK-OV-3, OV-90), and matured in the presence of polyinosinic:polycytidylic acid. We report the safety outcomes (safety analysis set, Parts 1 and 2 combined) along with the primary (progression-free survival (PFS)) and secondary (overall survival (OS)) efficacy endpoints. Efficacy endpoints were assessed in the modified intention-to-treat (mITT) analysis set in Part 1. RESULTS: Between November 2013 and March 2016, 99 patients were randomized. The mITT (Part 1) comprised 31, 29, and 30 patients in Groups A, B, and C, respectively. Baseline characteristics and DCVAC/OvCa exposure were comparable across the treatment arms. DCVAC/OvCa showed a good safety profile with treatment-emergent adverse events related to DCVAC/OvCa in 2 of 34 patients (5.9%) in Group A and 2 of 53 patients (3.8%) in Group B. Median PFS was 20.3, not reached, and 21.4 months in Groups A, B, and C, respectively. The HR (95% CI) for Group A versus Group C was 0.98 (0.48 to 2.00; p=0.9483) and the HR for Group B versus Group C was 0.39 (0.16 to 0.96; p=0.0336). This was accompanied by a non-significant trend of improved OS in Groups A and B. Median OS was not reached in any group after a median follow-up of 66 months (34% of events). CONCLUSIONS: DCVAC/OvCa and leukapheresis was not associated with significant safety concerns in this trial. DCVAC/OvCa sequential to CT was associated with a statistically significant improvement in PFS in patients undergoing first-line treatment of EOC. TRIAL REGISTRATION NUMBER: NCT02107937, EudraCT2010-021462-30.
650    _2
$a acetylcystein $x analogy a deriváty $7 D000111
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a zvířata $7 D000818
650    _2
$a protokoly protinádorové kombinované chemoterapie $x farmakologie $x terapeutické užití $7 D000971
650    _2
$a karboplatina $x farmakologie $x terapeutické užití $7 D016190
650    _2
$a epiteliální ovariální karcinom $x farmakoterapie $7 D000077216
650    _2
$a dendritické buňky $x imunologie $7 D003713
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunoterapie $x metody $7 D007167
650    _2
$a myši $7 D051379
650    _2
$a lidé středního věku $7 D008875
650    _2
$a paclitaxel $x farmakologie $x terapeutické užití $7 D017239
650    _2
$a mladý dospělý $7 D055815
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Cibula, David $u First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $1 https://orcid.org/0000000163879356 $7 jo20000074072
700    1_
$a Knapp, Pawel $u Department of Gynaecologic Oncology, Medical University of Bialystok, Bialystok, Poland
700    1_
$a Mallmann, Peter $u University Hospital of Cologne, Cologne, Germany
700    1_
$a Klat, Jaroslav $u Department of Gynecology and Obstetrics, University Hospital Ostrava and University of Ostrava, Ostrava, Czech Republic
700    1_
$a Minar, Lubos $u Department of Gynecology and Obstetrics, University Hospital Brno and Masaryk University, Brno, Czech Republic
700    1_
$a Bartos, Pavel $u Department of Gynecology and Obstetrics, Hospital Novy Jicin Novy Jicin, Novy Jicin, Czech Republic
700    1_
$a Chovanec, Josef $u Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Valha, Petr $u Department of Gynecology and Obstetrics, Hospital Ceske Budejovice, České Budějovice, Czech Republic
700    1_
$a Pluta, Marek $u Department of Obstetrics and Gynecology, 2nd Faculty of Medicine, University Hospital Motol, Prague, Czech Republic
700    1_
$a Novotny, Zdenek $u Department of Gynecology and Obstetrics, Faculty Hospital Plzen, Plzen, Czech Republic
700    1_
$a Spacek, Jiri $u Department of Obstetrics and Gynecology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Melichar, Bohuslav $u Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic
700    1_
$a Kieszko, Dariusz $u Oncological Center of the Lublin Region, Lublin, Poland
700    1_
$a Fucikova, Jitka $u Department of Immunology, Charles University, Praha, Czech Republic $u SOTIO a.s, Prague, Czech Republic $1 https://orcid.org/000000028423479X $7 xx0116819
700    1_
$a Hrnciarova, Tereza $u First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $u SOTIO a.s, Prague, Czech Republic
700    1_
$a Korolkiewicz, Roman Pawel $u SOTIO a.s, Prague, Czech Republic $1 https://orcid.org/0000000291880327
700    1_
$a Hraska, Marek $u SOTIO a.s, Prague, Czech Republic spisek@sotio.com hraska@sotio.com
700    1_
$a Bartunkova, Jirina $u SOTIO a.s, Prague, Czech Republic
700    1_
$a Spisek, Radek $u SOTIO a.s, Prague, Czech Republic spisek@sotio.com hraska@sotio.com
773    0_
$w MED00201262 $t Journal for immunotherapy of cancer $x 2051-1426 $g Roč. 10, č. 1 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34992091 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506131502 $b ABA008
999    __
$a ok $b bmc $g 1789227 $s 1162712
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 10 $c 1 $e - $i 2051-1426 $m Journal for immunotherapy of cancer $n J Immunother Cancer $x MED00201262
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace